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Letters to the Editor
Escherichia coli Isolate Coproducing 16S rRNA Methylase and CTX-M-Type
Extended-Spectrum -Lactamase Isolated from an Outpatient in
the United States
High-level resistance to aminoglycosides mediated by the
production of 16S rRNA methylase among various gram-
negative pathogens has been increasingly reported (4). Six
16S rRNA methylase enzymes have been identified: RmtA
to RmtD, ArmA, and NpmA (4, 9). We recently described
the emergence of ArmA among Acinetobacter baumannii
strains in North America (3). Here, we report the isolation
of an Escherichia coli strain coproducing 16S rRNA meth-
ylase RmtB and extended-spectrum -lactamase (ESBL)
CTX-M-65 from an ambulatory female with a history of
sickle-cell anemia. E. coli grew in a urine culture ordered as
part of her evaluation for chronic kidney disease. A review
of the records indicated that she had been hospitalized
briefly 4 months earlier, but the urine culture did not grow
E. coli during or after that hospitalization. This is the first
instance in which RmtB has been shown to be encoded on
the same plasmid as an ESBL.
The isolate, E. coli ECRB1, was highly resistant to cefotaxime
(MIC, 64 g/ml) and gentamicin, tobramycin, and amikacin
(MICs, 256 g/ml) but was susceptible to trimethoprim-sulfa-
methoxazole and ciprofloxacin by Etest (AB Biodisk, Solna,
Sweden). Transconjugants were obtained by the broth mating
method on Luria-Bertani plates containing 50 g of ri-
fampin/ml and 50 g of amikacin/ml by using E. coli XL1-Blue
Rifr as the recipient. Transformants of E. coli DH10B were
obtained on Luria-Bertani plates containing 50 g of amika-
cin/ml following electroporation with plasmids purified from
the parental strain. The MICs of cefotaxime (96 g/ml) and the
three aminoglycosides (128 g/ml) were high for both the
transconjugant and transformant strains. The results of PCR
analysis of whole-cell lysates for CTX-M genes (6) were posi-
tive for both strains. Direct sequencing of the entire structural
gene amplified from the transformant confirmed it to encode
CTX-M-65, a variant of CTX-M-14. Multiplex PCR analysis of
the transconjugant and transformant strains for 16S rRNA
methylase genes (4) revealed the presence of rmtB. The results
of PCR analysis for qepA, a quinolone efflux pump gene re-
ported to be carried on the same plasmid as rmtB (10), were
negative for the transconjugant and transformant strains.
A 2.9-kb BamHI insert containing rmtB could be cloned
from the transformant into vector pBCSK() (Stratagene,
La Jolla, CA) with E. coli DH10B as the host. This plasmid
conferred a high level of resistance to all three aminoglyco-
sides tested (MICs, 256 g/ml). Full sequencing of this
insert revealed a genetic arrangement similar to those re-
ported earlier (5, 10) in that the insert contained blaTEM-1 as
part of Tn3 upstream from rmtB (Fig. 1). However, the
putative transposase gene previously found downstream of
rmtB was replaced by the 3 end of another transposase gene
comprising IS26.
CTX-M-type ESBLs are increasingly associated with commu-
nity-acquired E. coli infections throughout the world, including
the United States (2, 8). rmtB has been found in strains carrying
blaCTX-M but, unlike armA (1, 7, 11), on a separate plasmid from
blaCTX-M. Our findings indicate, however, that rmtB may be cap-
tured by the same conjugative plasmid carrying blaCTX-M. The
spread of such multidrug resistance plasmids amongE. coli strains
has a potential impact on the empirical management of compli-
cated urinary tract infections that may be treated initially with
cephalosporins and aminoglycosides.
Nucleotide sequence accession number. The sequences de-
termined in this work have been deposited in GenBank under
accession no. EU213261 and EU213262.
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FIG. 1. Genetic support of rmtB. rmtB is flanked by Tn3 and IS26.
tnpR, resolvase gene; tnpA, transposase gene; tIR, terminal inverted
repeat of Tn3 (5-CTTAACGTGAGTTTTCGTTCCACTGAGCGTC
AGACCCC-3); IRR, right inverted repeat of IS26 (5-GGCACTGT
TGCAAA-3).
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